Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (8317)	5/9/2003 1:23:06 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

<NVGN> Tom, Yes, I have been keeping an eye on it. I thought the paper was a pretty solid piece of work, despite having its findings distorted in the associated PR. It's not common to see a drug that had essentially no effect on normal cells but a pretty marked one on cancer cells. (Typically chemo drugs kill everything in sight - they just kill normal cells a little less efficiently than cancer cells). It might not be that great as a monotherapy, but I would expect it to have good effect in combination therapy. I (like I think Rick) am a green tea and soy fan (at least in abstract in my case if not in practice <g>). A markedly souped-up genistein analog is a very appealing concept to me. Peter